MRK
Merck & Co., Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$150.15
−1.44%Sep 4, 2026, 00:42 UTC
Merck announced that China's National Medical Products Administration approved its PD-1 inhibitor Keytruda (pembrolizumab) for the neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma in adult patients with PD-L1 expression (CPS ≥1).
Source:Sep 3, 2026, 23:53 UTC
Electroninks, Merck, and Qualipoly Chemical formed a strategic partnership to build an advanced packaging ecosystem for semiconductor customers.
Source:Sep 3, 2026, 15:24 UTC
Cipla's U.S. unit entered an exclusive partnership with Qilu Pharmaceutical to license a biosimilar of Merck's Keytruda for the U.S. market.
Source:Aug 29, 2026, 21:30 UTC
The Australian Federal Government announced that KEYTRUDA (pembrolizumab) will be subsidised through the Pharmaceutical Benefits Scheme (PBS) for over 10,000 newly eligible Australians with advanced or metastatic cancers from 1 September 2026.
Aug 27, 2026, 20:45 UTC
The University of Queensland commemorates the 20th anniversary of the first dose of the HPV vaccine (Gardasil 9), developed by Ian Frazer and Jian Zhou, which has been administered over 600 million times worldwide and is credited with helping to end cervical cancer in Australia.
Source:Aug 26, 2026, 04:45 UTC
Four Democratic senators, led by Elizabeth Warren, sent a letter to Health Secretary Robert F. Kennedy Jr. questioning his disclosures regarding a $50 million settlement by Merck over Gardasil vaccine litigation, in which Kennedy had a financial interest before taking office.
Source:Aug 25, 2026, 09:21 UTC
Bank of New York Mellon Corp reduced its stake in Merck & Co., Inc. by 2.0% during the quarter, selling 373,190 shares, as disclosed in its Form 13F filing.
Source:Aug 25, 2026, 09:21 UTC
Bellars Harris Wealth Management LLC disclosed a new minority stake in Merck & Co., Inc. by purchasing 79,847 shares valued at approximately $10.26 million, as reported in its Form 13F filing.
Source:Aug 25, 2026, 07:57 UTC
ABN AMRO Bank N.V. reduced its stake in Merck & Co., Inc. by 7.6% during the quarter, selling 11,149 shares, according to its Form 13F filing.
Source:Aug 20, 2026, 06:48 UTC
Shares of CSPC Pharmaceutical Group surged over 15% in morning trading on August 20, 2026, driven by positive Phase 3 results of Moderna and Merck's personalized mRNA cancer therapy intismeran.
Source:Aug 19, 2026, 19:38 UTC
Biopharma stocks including AbbVie, Amgen, Eli Lilly, Johnson & Johnson, and Merck rallied on Wednesday, with Merck jumping 12.4%.
Source:Aug 19, 2026, 10:46 UTC
Merck and Moderna announced that the Phase 3 clinical trial of Intismeran met its primary endpoint, showing the vaccine prevents melanoma recurrence.
Aug 16, 2026, 13:46 UTC
Merck reported first-half 2026 results with a net loss of $5.575 billion due to a one-time acquisition charge, and total revenue of $32.893 billion, up 5% year-over-year.
Source:Aug 15, 2026, 15:46 UTC
Richard R. DeLuca, Executive Vice President and President of Merck Animal Health, sold 45,320 shares of Merck & Co., Inc. common stock over three days from August 10 to August 12, 2026, totaling approximately $5,942,369.
Source:Aug 10, 2026, 18:57 UTC
President Trump is expected to sign an executive order recommending the split of the MMR combination vaccine into three separate vaccines and the administration of childhood vaccines at separate visits.
Aug 8, 2026, 23:00 UTC
Uniquity Bio appointed Jason Moore as senior vice president of regulatory and quality.
Source:Aug 7, 2026, 03:07 UTC
Merck & Co.'s Ebola vaccine and Gilead Sciences' antiviral drug are set for wider use in eastern Democratic Republic of Congo to combat the fastest-growing Ebola outbreak on record.
Source:Aug 6, 2026, 10:45 UTC
The U.S. FDA accepted Merck's supplemental Biologics License Application for ENFLONSIA (clesrovimab-cfor) to expand its RSV lower respiratory tract disease indication to include children under two years at increased risk for severe RSV through their second season.
Source:Aug 4, 2026, 23:40 UTC
McDonald's and Merck reported earnings that beat analyst expectations.
Source:Aug 4, 2026, 15:16 UTC
Merck incurred costs related to its acquisition of Turnstone Biologics, a leukemia drug developer, which impacted its full-year EPS guidance.
Source:Aug 4, 2026, 10:34 UTC
Merck incurred a charge related to its acquisition of Terns Pharmaceuticals, which affected its profit guidance.
Aug 4, 2026, 10:30 UTC
Merck & Co., Inc. announced its financial results for the second quarter of 2026.
Aug 3, 2026, 18:02 UTC
Merck & Co. presented its HIV treatment and prevention strategy at an investor event, highlighting Phase III results for a once-weekly oral HIV regimen and plans for a monthly oral PrEP candidate.
Source:Jul 31, 2026, 18:10 UTC
Merck acquired Terns Pharmaceuticals and Cidara Therapeutics to broaden its oncology and virology portfolios.
Source:Jul 31, 2026, 18:10 UTC
Merck launched subcutaneous Qlex, extending the lifecycle of Keytruda.
Source:Jul 31, 2026, 14:30 UTC
Rappta Therapeutics, founded by Goutham Narla, was acquired by Merck, which will develop its treatment for endometrial and lung cancer.
Source:Jul 21, 2026, 14:00 UTC
Gilead Sciences and Merck & Co. announced phase 3 clinical trial results for their two-drug combination lenacapavir and islatravir, positioning it as the first complete weekly oral HIV treatment.
Source:Jun 9, 2026, 20:36 UTC
Gilead and Merck report positive phase III results for once-weekly HIV regimen islatravir/lenacapavir.
Source:
Page 1Next →